ivis imaging system  (Revvity)

Journal: Bioactive Materials

Article Title: AdMSC spheroids encapsulating antioxidant hybrid protein carrier for irradiation-damaged salivary gland repair

doi: 10.1016/j.bioactmat.2026.03.049

Figure Lengend Snippet: In vivo retention and clearance kinetics of DiR-labeled AdMSC spheroids after injection into mouse salivary glands. (a) DiR-labeled AdMSC spheroids or spheroid + GC (untreated, spheroid, spheroid + GC 5% w/v, spheroid + GC 7% w/v) were injected into the IR-damaged mouse salivary gland, and their fluorescence signals were monitored by IVIS from days 1 to 28 until no detectable signal remained. (b) Quantification of the average radiant efficiency in the salivary gland region over time. (c) At day 28 post-injection, major organs (heart, liver, spleen, kidneys, lungs, and stomach) were harvested and imaged by IVIS to assess DiR signals. Data are presented as mean ± SD (n = 3 or n = 4). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ns P > 0.05, ∗ P ≤ 0.05, ∗∗ P ≤ 0.01, and ∗∗∗ P ≤ 0.001.

Article Snippet: For in vivo fluorescence imaging, mice were anesthetized and scanned using an IVIS imaging system (IVIS Lumina S5, PerkinElmer) at predetermined time points (1, 3, 5, 7, 10, 14, 21, and 28 days) with excitation/emission settings appropriate for DiR (typically Ex 748 nm/Em 780 nm).

Techniques: In Vivo, Labeling, Injection, Fluorescence

Journal: Bioactive Materials

Article Title: Nose-to-brain administration of cannabidiol-loaded polymeric micelles improves the core behavioral symptoms of autism spectrum disorder

doi: 10.1016/j.bioactmat.2026.03.019

Figure Lengend Snippet: Pharmacokinetics of 25% w/w CBD-loaded Pluronic® F127 polymeric micelles in ASD-like rats. (A) IVIS fluorescence micrographs of rat brains at different time points after i.n. administration of NIR-797-labeled CBD-loaded polymeric micelles, as imaged by IVIS (n = 4). (B) Fluorescence radiance intensity profiles in the brain of rat (n = 4). (C) IVIS fluorescence micrographs of rat olfactory bulbs 90 min after i.n. administration of NIR-797-labeled CBD-loaded polymeric micelles, as imaged by IVIS (n = 4). (D) CBD concentration in rat brains following the i.n. and oral administration of 25% w/w CBD-loaded Pluronic® F127 polymeric micelles and i.n. administration of CBD dissolved in propylene glycol. (E) CBD concentration in rat plasma following the i.n. and oral administration of 25% w/w CBD-loaded Pluronic® F127 polymeric micelles and i.n. administration of CBD dissolved in propylene glycol. In all the PK studies, the i.n. and oral CBD dose was 5 and 15 mg/kg, respectively. All data are presented as mean ± S.E. (n = 4).

Article Snippet: Imaging was performed using an IVIS® Spectrum CT system from PerkinElmer (Waltham, MA, USA).

Techniques: Drug discovery, Fluorescence, Labeling, Olfactory, Concentration Assay, Clinical Proteomics

Journal: Bioactive Materials

Article Title: Sustained release PLGA microspheres loaded with a bone-affinity Bmp2 enhance fracture healing and mitigate heterotopic ossification

doi: 10.1016/j.bioactmat.2026.02.050

Figure Lengend Snippet: Design and validation of bone-targeted Bmp2. a. Schematic representation of the Bmp2/D-Bmp2 plasmid constructs and the structure predicted by AlphaFold3. b. Immunofluorescence staining of HEK-293T cells transfected with the plasmids: phalloidin (green), DAPI (blue), and Alexa Fluor 647-conjugated anti-Flag antibodies (red). Scale bar: 10 μm. c. SDS-PAGE of purified proteins. d. Western blot validation of protein expression. e. Bmp2 activity reporter assay: schematic of the luciferase reporter system (left), representative fluorescence images, and statistical analysis of firefly luciferase activity by in vivo imaging system (IVIS) (a.u.: arbitrary units) (right, n = 3 per group). f. qPCR analysis of Bmp2 signaling pathway-related mRNA levels in MC3T3-E1 cells treated with the Bmp2 or D-Bmp2 protein (n = 3 per group). g, h. Western blot (g) and quantification of Bmp2 pathway-related protein expression in treated MC3T3-E1 cells (h) (n = 3 per group). i. Schematic of the HA-coated ELISA plate and HA-binding affinity assay (n = 3 per group). j. Tissue-specific binding assay of Bmp2 or D-Bmp2: Mouse muscle slices (left, scale bar: 100 μm) and undecalcified femur slices (right, scale bar: 200 μm) stained with AF647-conjugated anti-Flag antibodies. The data are presented as the means ± standard deviations (SDs). One-way ANOVA was used for multiple comparisons. Significance levels: ns (not significant), ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: After 24 h, the medium was changed to contain either Bmp2 or D-Bmp2 in DMEM, and the cells were further cultured for another 24 h. After the supernatant was removed, D-luciferin potassium salt (Beyotime, China) was added, and the firefly fluorescence signal was recorded using an in vivo imaging system (IVIS) (PerkinElmer, USA).

Techniques: Biomarker Discovery, Plasmid Preparation, Construct, Immunofluorescence, Staining, Transfection, SDS Page, Purification, Western Blot, Expressing, Activity Assay, Reporter Assay, Luciferase, Fluorescence, In Vivo Imaging, Enzyme-linked Immunosorbent Assay, Binding Assay

Journal: Molecular Therapy Oncology

Article Title: NeuroD1 gene therapy inhibits glioma growth and extends life span through in vivo reprogramming approach

doi: 10.1016/j.omton.2026.201205

Figure Lengend Snippet: scAAV6-NeuroD1 reduces tumor size and inhibits cell proliferation in a U87 GBM orthotopic mouse model Representative images of DAPI immunostaining (A) and hematoxylin and eosin (H&E) staining (B) comparing tumor area in control and scAAV6-NeuroD1-treated groups at 14 days post-tumor transplantation (DPT). Scale bars, 1,000 μm. (C) Quantification of tumor area using DAPI immunostaining images, showing a significant reduction in the scAAV6-NeuroD1-treated group relative to the control. Data are presented as mean ± SEM. ∗∗∗ p < 0.001 by unpaired two-tailed Student’s t test. (D) Representative images of Ki67 immunostaining demonstrate reduced cell proliferation in the scAAV6-NeuroD1-treated group. Scale bars, 1,000 μm (E) Time course measurement of IVIS signals showing comparison of bioluminescent flux between control and scAAV6-NeuroD1-treated group. Data are presented as mean ± SEM ( n = 5–6 per group). ∗∗∗ p < 0.001 by two-way ANOVA followed by Tukey’s post hoc test. (F) RT-qPCR analysis of Ki67 mRNA expression confirms a significant decrease in proliferation markers in the scAAV6-NeuroD1-treated group. ∗∗∗ p < 0.001 by unpaired two-tailed Student’s t test.

Article Snippet: Tumor progression was monitored using an IVIS imaging system (Caliper Life Sciences, USA) 24 h before treatment (days 5, 10, and 15) following intraperitoneal injection of D-luciferin (Solarbio, China).

Techniques: Immunostaining, Staining, Control, Transplantation Assay, Two Tailed Test, Comparison, Quantitative RT-PCR, Expressing